Pharmaceutical Owner Arrested Following Tragic Deaths of 20 Children from Contaminated Cough Syrup

In a devastating public health crisis, law enforcement authorities have taken into custody the proprietor of a Tamil Nadu-based pharmaceutical company after his products were implicated in the deaths of at least 20 children across multiple Indian states.

The Arrest

S Ranganathan, proprietor of Sresan Pharma, was apprehended by Madhya Pradesh police in Chennai during the late hours of October 8, 2025. The arrest came after authorities announced a reward of ₹20,000 for information leading to his capture. He is now facing legal proceedings and will be transferred to Chhindwara, Madhya Pradesh, following transit remand approval from a Chennai court.

The Deadly Contamination

The tragedy centers around Coldrif, a pediatric cough formulation marketed for common cold symptoms including runny nose, sneezing, and sore throat. What should have been a routine remedy for children's ailments turned fatal due to severe contamination with diethylene glycol (DEG), a toxic industrial compound typically found in adhesives, inks, and antifreeze products.

Medical experts identify DEG as particularly dangerous, capable of inflicting severe damage to vital organs including the kidneys, liver, and nervous system. The young victims reportedly experienced acute kidney complications after consuming the syrup, leading to their untimely deaths. The fatalities have been reported primarily in Madhya Pradesh, with additional cases emerging from Rajasthan.

Shocking Regulatory Violations

An official inspection conducted by the Tamil Nadu Drugs Control Authority exposed alarming safety breaches at Sresan Pharma's manufacturing facility in Kancheepuram district:

• Extreme contamination levels: Laboratory analysis revealed DEG concentrations reaching 48% in the syrup samples—a staggering 480 times higher than the permissible limit of 0.1%
• Absence of GMP certification: The facility operated without mandatory Good Manufacturing Practices certification, a fundamental requirement for pharmaceutical production
• Lack of quality control: The manufacturer failed to conduct proper quality testing on raw materials and active pharmaceutical ingredients

Regulatory Response

Following these discoveries, authorities have implemented comprehensive measures:

• Immediate cessation of all production activities at Sresan Pharma
• Suspension of the company's manufacturing license
• Complete seizure of existing inventory
• Nationwide sales prohibition across at least nine Indian states
• Issuance of show-cause notices to the company

The Central Drugs Standard Control Organisation (CDSCO) has acknowledged systemic weaknesses in manufacturing oversight, revealing that numerous pharmaceutical operations across the country have been operating with inadequate quality control protocols.

Broader Implications

This tragedy raises urgent questions about pharmaceutical regulation and oversight in India's generic drug industry. The incident underscores the critical importance of:

• Stringent enforcement of manufacturing standards
• Regular and thorough facility inspections
• Mandatory quality testing of all ingredients
• Swift action against non-compliant manufacturers
• Enhanced monitoring of medications intended for vulnerable populations, particularly children

As the investigation continues, authorities are working to determine the full scope of the contamination and whether additional products or facilities may be implicated. The case serves as a sobering reminder of the potential consequences when profit motives override public safety and regulatory compliance in the pharmaceutical sector.

The families of the affected children await justice as legal proceedings move forward against those responsible for this preventable tragedy.